DBBHA-FEAS: evidencing technical and commercial feasibility of producing hyaluronic acid utilising a new highly productive strain of cyanobacteria.

**DBBHA-FEAS: evidencing technical and commercial feasibility of producing hyaluronic acid utilising a new highly productive strain of cyanobacteria.**

A UK-based SME, Deep Blue Biotech Ltd, is collaborating with CPI in this 6 month feasibility study. The project focuses on two primary objectives. Firstly, we aim to develop our cyanobacteria platform, leveraging the rapid growth and high biomass accumulation of a recently identified highly productive strain to enhance our production capabilities.

Secondly, in partnership with CPI, we will conduct a comprehensive techno-economic analysis to validate both the technical and commercial viability of our approach.

This analysis will focus on refining the strain and crucially optimising downstream processing. By simplifying the purification process, we aim to achieve price competitiveness while also delivering superior quality, enhanced sustainability, and logistical advantages.

Post project we will refine and scale our proprietary metabolic engineering approach before moving into the pilot phase in collaboration with CPI. By 2031, we expect HA's domestic and localised supply chain to generate internal revenues of £177 million and profits of £35 million, strengthening our commitment to sustainable development.